A pharmacokinetic and safety evaluation of single oral doses of eszopiclone in pediatric subjects from 6 to 17 years of age with attention deficit hyperactivity disorder and insomnia
A pharmacokinetic and safety evaluation of single oral doses of eszopiclone in pediatric subjects from 6 to 17 years of age with attention deficit hyperactivity disorder and insomnia
"If you think your design is perfect, it’s only because you haven’t shown it to someone else."
